Joan S Lewis-Wambi

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. pmc Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast Cancer Res 10:R104. 2008
  2. pmc The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1
    Joan S Lewis-Wambi
    Women s Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Mol Pharmacol 80:610-20. 2011
  3. pmc Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Cancer Res 11:206. 2009
  4. pmc Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, United States
    J Steroid Biochem Mol Biol 114:33-9. 2009
  5. pmc New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 18:S10-7. 2009
  6. pmc Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    J Steroid Biochem Mol Biol 102:128-38. 2006
  7. pmc Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Proc Natl Acad Sci U S A 108:18879-86. 2011
  8. pmc Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen
    Philipp Y Maximov
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Med Chem 53:3273-83. 2010
  9. pmc Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Eur J Cancer 44:1770-9. 2008
  10. ncbi request reprint Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Dis 24:93-105. 2005

Collaborators

Detail Information

Publications15

  1. pmc Buthionine sulfoximine sensitizes antihormone-resistant human breast cancer cells to estrogen-induced apoptosis
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast Cancer Res 10:R104. 2008
    ..In the present study, we evaluated whether buthionine sulfoximine (BSO), a potent inhibitor of glutathione (GSH) synthesis, is capable of sensitizing antihormone resistant MCF-7:2A cells to estradiol-induced apoptosis...
  2. pmc The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1
    Joan S Lewis-Wambi
    Women s Cancer Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Mol Pharmacol 80:610-20. 2011
    ..Together, these findings indicate that BZA is distinct from other SERMs in its ability to inhibit hormone-independent breast cancer cell growth and to regulate ERα and cyclin D1 expression in resistant cells...
  3. pmc Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit?
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Cancer Res 11:206. 2009
    ..This finding has implications for the control of breast cancer with low-dose estrogen and other targeted therapeutic drugs...
  4. pmc Potential of l-buthionine sulfoximine to enhance the apoptotic action of estradiol to reverse acquired antihormonal resistance in metastatic breast cancer
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, United States
    J Steroid Biochem Mol Biol 114:33-9. 2009
    ....
  5. pmc New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 18:S10-7. 2009
    ..The question to be addressed is how we can amplify the new biology of oestrogen-induced apoptosis to create more complete responses in exhaustively antihormone treated metastatic breast cancer...
  6. pmc Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    J Steroid Biochem Mol Biol 102:128-38. 2006
    ....
  7. pmc Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time
    Eric A Ariazi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Proc Natl Acad Sci U S A 108:18879-86. 2011
    ..Therefore, these data indicate that E(2) induced apoptosis through ERS and inflammatory responses in advanced antihormone-resistant breast cancer...
  8. pmc Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen
    Philipp Y Maximov
    Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    J Med Chem 53:3273-83. 2010
    ..Using available conformations of the ER liganded with 4OHTAM or diethylstilbestrol, the TPEs optimally occupy the 4OHTAM ER conformation that expresses Asp351...
  9. pmc Overexpression of CEACAM6 promotes migration and invasion of oestrogen-deprived breast cancer cells
    Joan S Lewis-Wambi
    Department of Medical Sciences, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Eur J Cancer 44:1770-9. 2008
    ..In conclusion, our findings establish CEACAM6 as a unique mediator of migration and invasion of drug resistant oestrogen-deprived breast cancer cells and suggest that this protein could be an important biomarker of metastasis...
  10. ncbi request reprint Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs)
    Joan S Lewis-Wambi
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Dis 24:93-105. 2005
    ..This review article discusses the significant and continuing value of SERMs for the treatment of postmenopausal ER-positive breast cancer...
  11. ncbi request reprint The apoptotic action of estrogen following exhaustive antihormonal therapy: a new clinical treatment strategy
    V Craig Jordan
    Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Breast 14:624-30. 2005
    ..Low-dose estrogen could be used to debulk patients followed by fulvestrant in a low estrogen environment (aromatase treatment) to maintain tumor control...
  12. ncbi request reprint Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance
    Joan S Lewis
    Fox Chase Cancer Center, Alfred G Knudson Chair of Cancer Research, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Mutat Res 591:247-63. 2005
    ....
  13. ncbi request reprint Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation
    Joan S Lewis
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Natl Cancer Inst 97:1746-59. 2005
    ..Here, we investigated the role of the mitochondrial apoptotic pathway in this process...
  14. ncbi request reprint Activation of cyclin D1 by estradiol and spermine in MCF-7 breast cancer cells: a mechanism involving the p38 MAP kinase and phosphorylation of ATF-2
    Joan S Lewis
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, New Jersey, NJ 08903, USA
    Oncol Res 15:113-28. 2005
    ..These results indicate that spermine can enhance E2-induced cell signaling and cyclin D1 transcription by activation of the p38 MAP kinase and phosphorylation of ATF-2, contributing to breast cancer cell proliferation...
  15. ncbi request reprint Differential effects of 16alpha-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells
    Joan S Lewis
    Department of Medicine, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    J Mol Endocrinol 34:91-105. 2005
    ..The binding of ATF-2 was inhibited by the presence of 2-ME2. These results show that 2-ME2 can downregulate cyclin D1 and thereby cell cycle progression by a mechanism involving the disruption of ATF-2 binding to cyclin D1 promoter...

Research Grants2

  1. The new biology of estrogen action in aromatase resistance breast cancer cells
    Joan Lewis Wambi; Fiscal Year: 2007
    ..Breast cancer thus represents a major health problem; hence, a strategy to understand and subvert the acquisition of resistance to current treatment modalities would be a valuable therapeutic advantage. ..